



IDS Form PTO/SB/08: Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	10/509,280
Filing Date	May 5, 2005
First Named Inventor	Bernat VIDAL JUAN
Art Unit	1624
Examiner Name	Susanna Moore
Attorney Docket Number	09605.0002

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	1	WO 86/02551	09 MAY 1986			
	2	EP 0480659	15 APR 1992			

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Translation <sup>6</sup>
	3	Bettina Grahner, et al., "Synthesis and structure-activity relationships of deazaxanthines: analogs of potent A <sub>1</sub> - and A <sub>2</sub> -adenosine receptor antagonists," Journal of Medicinal Chemistry, 37(10):1526-1534 (1994).		
	4	Igor Feoktistov, et al., "Adenosine A <sub>2B</sub> receptors," Pharmacological Reviews, 49(4):381-402 (1997).		
	5	Kenneth A. Jacobson, et al., "Functionalized congeners of 1,3-dialkylxanthines: preparation of analogues with high affinity for adenosine receptors," Journal of Medicinal Chemistry, 28(9):1334-1340 (1985).		
	6	Junich Shimada, et al., "8-polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A <sub>1</sub> -adenosine receptors," Journal of Medicinal Chemistry, 35(5):924-930 (1992).		
	7	Kim Yong-Chul, et al., "Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A <sub>2B</sub> adenosine receptors," Journal of Medicinal Chemistry, 43(6):1165-1172 (2000).		
	8	Kim Yong-Chul, et al., "Acyl-hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A <sub>2B</sub> adenosine receptors," Drug Development Research, 47(4):178-188 (1999).		
	9	Yoneda Fumio, et al., "Syntheses and properties of 3-hydroxy-4,6-dimethylpyrrolo[3,2-d]pyrimidine-5-7(4H,6H)-dione (9-hydroxy-9-deazatheophylline) derivatives," Chem. Pharma Bull, 30(9):3187-1396 (1982).		
	10	Helmut Fenner, et al., "Pyrrolo [3, 2 -d] pyrimidine aus pyrimido [4.5 - b][1.4] thiazinen," Tetrahedron Letters, 44:4185-4188 (1971).		
	11	Shigeo Senda, et al., "Pyrimidine derivatives and related compounds. XXIX. Photoreductive cyclization of 5-nitro-6-styryl(or anilino)uracil derivatives to pyrrolo[3,2-d]pyrimidine and alloxazine derivatives," Chem. Pharma. Bull, 25(4):563-568 (1977).		
	12	Hermut Fenner, et al., "9-deazapurine aus pyrimido[4.5-b] [1.4] thiazinen," Arch. Pharma, 311(2):153-161 (1978).		
	13	Robert F. Burns, et al., "Adenosine receptors in brain membranes: binding of N <sup>6</sup> -cyclohexyl[ <sup>3</sup> H]adenosine and 1,3-diethyl-8-[ <sup>3</sup> H]phenylxanthine," Proc. Natl. Acad. Sci. USA, 77(9):5547-555 (1980).		
	14	Cristina Esteve, et al, "New pyrrolopyrimidin-6-yl benzenesulfonamides: potent A <sub>2B</sub> adenosine receptor antagonists," Bioorganic & Medicinal Chemistry Letters, 16:3642-3645 (2006).		
	15	Office Action from U.S. Application No. 10/481,728, dated February 26, 2007.		

Examiner Signature	Date Considered	
--------------------	-----------------	--

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.